Trial Profile
Metabolism and disposition of the alphav-integrin ss3/ss5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2015
Price :
$35
*
At a glance
- Drugs Cilengitide (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- 09 Nov 2015 New trial record